JP2011219478A5 - - Google Patents

Download PDF

Info

Publication number
JP2011219478A5
JP2011219478A5 JP2011104172A JP2011104172A JP2011219478A5 JP 2011219478 A5 JP2011219478 A5 JP 2011219478A5 JP 2011104172 A JP2011104172 A JP 2011104172A JP 2011104172 A JP2011104172 A JP 2011104172A JP 2011219478 A5 JP2011219478 A5 JP 2011219478A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr1
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011104172A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011219478A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2011104172A priority Critical patent/JP2011219478A/ja
Priority claimed from JP2011104172A external-priority patent/JP2011219478A/ja
Publication of JP2011219478A publication Critical patent/JP2011219478A/ja
Publication of JP2011219478A5 publication Critical patent/JP2011219478A5/ja
Pending legal-status Critical Current

Links

JP2011104172A 2009-03-19 2011-05-09 関節リウマチ治療剤 Pending JP2011219478A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011104172A JP2011219478A (ja) 2009-03-19 2011-05-09 関節リウマチ治療剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009067358 2009-03-19
JP2009067358 2009-03-19
JP2011104172A JP2011219478A (ja) 2009-03-19 2011-05-09 関節リウマチ治療剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010511837A Division JP4809930B2 (ja) 2009-03-19 2010-03-19 関節リウマチ治療剤

Publications (2)

Publication Number Publication Date
JP2011219478A JP2011219478A (ja) 2011-11-04
JP2011219478A5 true JP2011219478A5 (enExample) 2013-05-02

Family

ID=42739764

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010511837A Active JP4809930B2 (ja) 2009-03-19 2010-03-19 関節リウマチ治療剤
JP2011104172A Pending JP2011219478A (ja) 2009-03-19 2011-05-09 関節リウマチ治療剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010511837A Active JP4809930B2 (ja) 2009-03-19 2010-03-19 関節リウマチ治療剤

Country Status (5)

Country Link
JP (2) JP4809930B2 (enExample)
KR (1) KR101314880B1 (enExample)
RU (1) RU2524152C2 (enExample)
TW (1) TWI457134B (enExample)
WO (1) WO2010107108A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN10515A (enExample) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
TWI438208B (zh) 2007-01-23 2014-05-21 Chugai Pharmaceutical Co Ltd 抑制慢性排斥反應之藥劑
CA2728243C (en) 2008-06-05 2020-03-10 National Cancer Center Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
ES2932398T3 (es) 2010-05-28 2023-01-18 Chugai Pharmaceutical Co Ltd Potenciador de la respuesta de las células T antitumorales
EP3009518B1 (en) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
US10697883B2 (en) 2015-05-19 2020-06-30 National Center Of Neurology And Psychiatry Method for determining application of therapy to multiple sclerosis (MS) patient
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
KR102771895B1 (ko) 2017-10-20 2025-02-21 가꼬우호우징 효고 이카다이가쿠 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
US20210363238A1 (en) 2018-01-31 2021-11-25 Motokazu Kato Therapeutic agent for asthma containing il-6 inhibitor
EP3949989A4 (en) 2019-03-29 2022-12-14 Chugai Seiyaku Kabushiki Kaisha Anti il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function
KR20220019670A (ko) 2019-04-17 2022-02-17 고쿠리츠다이가쿠호진 히로시마다이가쿠 Il-6 저해제 및 ccr2 저해제를 조합하여 투여하는 것을 특징으로 하는 비뇨기암의 치료제
US20240158518A1 (en) 2021-03-12 2024-05-16 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for treatment or prevention of myasthenia gravis
WO2025198912A1 (en) 2024-03-21 2025-09-25 Hoffmann-La Roche Inc. Methods of treating myasthenia gravis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL182089B1 (en) * 1994-10-21 2001-11-30 Chugai Pharmaceutical Co Ltd Pharmaceutic compositions for treating diseases caused by production of il-6
US8993319B2 (en) * 2004-12-28 2015-03-31 Innate Pharma S.A. Monoclonal antibodies against NKG2A
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
WO2009010539A2 (en) * 2007-07-19 2009-01-22 Ablynx. N.V. Receptor for interleukin-6 (il-6) from macaca fascicularis
ES2687808T3 (es) * 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
AU2008304756B8 (en) * 2007-09-26 2015-02-12 Chugai Seiyaku Kabushiki Kaisha Anti-IL-6 receptor antibody
PT2708559T (pt) * 2008-04-11 2018-05-16 Chugai Pharmaceutical Co Ltd Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules

Similar Documents

Publication Publication Date Title
JP2011219478A5 (enExample)
JP2012136541A5 (enExample)
JP2013517277A5 (enExample)
JP2017176174A5 (enExample)
JP2012507294A5 (enExample)
RU2011142183A (ru) Средство для лечения ревматоидного артрита
JP2014205674A5 (enExample)
JP2013539454A5 (enExample)
PH12014500089A1 (en) Antibodies that bind to ox40 and their uses
WO2012006596A3 (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
HRP20211343T1 (hr) Protutijela protiv dkk-1
HRP20192295T1 (hr) Optimizirana monoklonska protutijela protiv inhibitora faktora tkivnog puta (tfpi)
JP2008538564A5 (enExample)
JP2015522252A5 (enExample)
HRP20161740T1 (hr) Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
JP2018510132A5 (enExample)
JP2018536393A5 (enExample)
JP2014074046A5 (enExample)
JP2011528902A5 (enExample)
JP2012010714A5 (enExample)
JP2019500327A5 (enExample)
JP2012126742A5 (enExample)
JP2007051159A5 (enExample)
JP2014237714A5 (enExample)